Hartmut Doehner MD

Dr. H. Dohner is a Professor of Medicine, since 1999 he is Medical Director of the Department of Internal Medicine III (Hematology, Oncology, Palliative Medicine, Rheumatology, and Infectious Diseases) of Ulm University Hospital, 2006-2021 Director of the Comprehensive Cancer Center Ulm (since July 2021 Deputy Director), since 2020 member of the Scientific Steering Committee of the National Center for Tumor Diseases (NCT), and since 2012 Coordinating Investigator of the Collaborative Research Center SFB 1074 “Experimental Models and Clinical Translation in Leukemia”.

Dr. Dohner studied Medicine at the Universities of Regensburg, Freiburg, and Montpellier (France). He received his training in Hematology and Medical Oncology at the University of Heidelberg (Prof. Dr. W. Hunstein). Between 1988 and 1990, he spent a two-year period as a post-doctoral associate in the Department of Medicine, Division of Oncology (Prof. Clara D. Bloomfield), and the Department of Laboratory Medicine and Pathology, Division of Medical Genetics (Prof. Diane C. Arthur), University of Minnesota, Minneapolis, USA.

Dr. Dohner is an expert in the conduct of clinical trials and in the identification, characterization and clinical diagnosis of genetic changes in hematologic malignancies, including both acute and chronic leukemias. Dr. Dohner is chairman of the German-Austrian AML Study Group (AMLSG). His Department harbors the genetic reference laboratory for several multicenter trial groups, including the AMLSG, the German Study Group for Myeloproliferative Neoplasms (GSG-MPN), the German CLL Study Group (DCLLSG), and the German Study Group for Multiple Myeloma (DSMM).

Dr. Dohner held and was holding multiple leadership positions in the scientific community of hematology/oncology including Member of the Executive Board of the European Hematology Association (EHA) (2007-2011); Member of the Hinterzartener Kreis for Krebsforschung, Deutsche Forschungsgemeinschaft (2008-2012); Member of the Clinical Advisory Committee of the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008 and 2016; Member of the Myeloid Neoplasia Committee of the American Society of Hematology (2011-2014); Member of the Advisory Committee of the International Working Group in CLL (IWCLL); Member of the Nomination Committee of the European Hematology Association (EHA) (2014-2018); Member of the Committee “Klinische Forschung, kliniknahe Grundlagenforschung” of the Deutsche Krebshilfe (2015-2018); Member of the Scientific Committee, European School of Hematology (ESH) (2018-2020).